Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Vaccine ; 34(35): 4235-4242, 2016 07 29.
Article in English | MEDLINE | ID: mdl-27317455

ABSTRACT

Glycoconjugate vaccines are made of carbohydrate antigens covalently bound to a carrier protein to enhance their immunogenicity. Among the different carrier proteins tested in preclinical and clinical studies, five have been used so far for licensed vaccines: Diphtheria and Tetanus toxoids, the non-toxic mutant of diphtheria toxin CRM197, the outer membrane protein complex of Neisseria meningitidis serogroup B and the Protein D derived from non-typeable Haemophilus influenzae. Availability of novel carriers might help to overcome immune interference in multi-valent vaccines containing several polysaccharide-conjugate antigens, and also to develop vaccines which target both protein as well saccharide epitopes of the same pathogen. Accordingly we have conducted a study to identify new potential carrier proteins. Twenty-eight proteins, derived from different bacteria, were conjugated to the model polysaccharide Laminarin and tested in mice for their ability in inducing antibodies against the carbohydrate antigen and eight of them were subsequently tested as carrier for serogroup meningococcal C oligosaccharides. Four out of these eight were able to elicit in mice satisfactory anti meningococcal serogroup C titers. Based on immunological evaluation, the Streptococcus pneumoniae protein spr96/2021 was successfully evaluated as carrier for serogroups A, C, W, Y and X meningococcal capsular saccharides.


Subject(s)
Carrier Proteins/chemistry , Glycoconjugates/chemistry , Polysaccharides, Bacterial/immunology , Vaccines, Conjugate/chemistry , Animals , Antibodies, Bacterial/blood , Antibody Formation , Glucans/chemistry , Immunogenicity, Vaccine , Mice , Mice, Inbred BALB C , Neisseria meningitidis, Serogroup C , Recombinant Proteins/chemistry , Serum Bactericidal Antibody Assay , Vaccines, Conjugate/immunology
3.
Vaccine ; 34(20): 2334-41, 2016 Apr 29.
Article in English | MEDLINE | ID: mdl-27015733

ABSTRACT

Glycoconjugate vaccines are composed of capsular polysaccharides (CPSs) of a pathogenic bacteria covalently linked to carrier proteins. Pre-exposure to the carrier is known to influence the efficacy of the glycoconjugate, by inducing enhanced or suppressed anti-CPS response. Following our previous work on the immunogenicity of diphtheria toxin mutant CRM197 and formaldehyde-treated diphtheria toxoid (DT) as carriers for meningococcal A (MenA) conjugates in mouse model, we further investigated the role of the carrier on the immunological response to glycoconjugate vaccines. We previously showed that high dosage DT priming could result in carrier-induced epitopic suppression (CIES), an event that did not occur for CRM197 priming, and we observed that anti-DT IgGs could cross-react with DT based conjugates in vitro. Here, we confirmed the cross-reactivity of anti-carrier IgGs with DT conjugates in vivo. Furthermore, we analyzed the splenocytes of animals primed with the carrier and subsequently immunized with the MenA conjugate. Pre-exposure to the carrier protein, both CRM197 and DT, resulted in increased carrier-specific plasma and memory B cell response. However, only for CRM197 priming an enhanced carbohydrate-specific plasma cell response was observed. Analysis of circulating IgGs confirmed these observations. Memory to the CPS resulted to be non-influenced by carrier priming. Analysis of T helper response showed an enhancement effect for CRM197 priming, while DT priming resulted in constrained T cell activation. Stimulation with CRM197, which does not require formaldehyde detoxification, of splenocytes from animal immunized with DT suggested that the formaldehyde treatment used to produce DT might be the cause of limited presentation of the antigen to the T cells. We concluded that the dominant carrier-specific B cell response in case of limited T cell recruitment might explain the previously observed CIES phenomenon in case of DT priming.


Subject(s)
Bacterial Proteins/immunology , Carrier Proteins/immunology , Diphtheria Toxoid/immunology , Glycoconjugates/immunology , Meningococcal Vaccines/immunology , Adaptive Immunity , Animals , Antibodies, Bacterial/blood , B-Lymphocytes/immunology , Immunoglobulin G/blood , Immunologic Memory , Lymphocyte Activation , Mice, Inbred BALB C , T-Lymphocytes/immunology , Vaccines, Conjugate/immunology
4.
Vaccine ; 33(2): 314-20, 2015 Jan 03.
Article in English | MEDLINE | ID: mdl-25448110

ABSTRACT

Glycoconjugate vaccines play an enormous role in preventing infectious diseases. The main carrier proteins used in commercial conjugate vaccines are the non-toxic mutant of diphtheria toxin (CRM197), diphtheria toxoid (DT) and tetanus toxoid (TT). Modern childhood routine vaccination schedules include the administration of several vaccines simultaneously or in close sequence, increasing the concern that the repeated exposure to conjugates based on these carrier proteins might interfere with the anti-polysaccharide response. Extending previous observations we show here that priming mice with CRM197 or DT does not suppress the response to the carbohydrate moiety of CRM197 meningococcal serogroup A (MenA) conjugates, while priming with DT can suppress the response to DT-MenA conjugates. To explain these findings we made use of biophysical and immunochemical techniques applied mainly to MenA conjugates. Differential scanning calorimetry and circular dichroism data revealed that the CRM197 structure was altered by the chemical conjugation, while DT and the formaldehyde-treated form of CRM197 were less impacted, depending on the degree of glycosylation. Investigating the binding and avidity properties of IgGs induced in mice by non-conjugated carriers, we found that CRM197 induced low levels of anti-carrier antibodies, with decreased avidity for its MenA conjugates and poor binding to DT and respective MenA conjugates. In contrast, DT induced high antibody titers able to bind with comparable avidity both the protein and its conjugates but showing very low avidity for CRM197 and related conjugates. The low intrinsic immunogenicity of CRM197 as compared to DT, the structural modifications induced by glycoconjugation and detoxification processes, resulting in conformational changes in CRM197 and DT epitopes with consequent alteration of the antibody recognition and avidity, might explain the different behavior of CRM197 and DT in a carrier priming context.


Subject(s)
Bacterial Proteins/chemistry , Bacterial Proteins/immunology , Diphtheria Toxoid/immunology , Glycoconjugates/immunology , Meningococcal Vaccines/immunology , Vaccines, Conjugate/chemistry , Vaccines, Conjugate/immunology , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antibody Affinity , Calorimetry, Differential Scanning , Circular Dichroism , Diphtheria Toxoid/chemistry , Epitopes/chemistry , Epitopes/immunology , Glycoconjugates/chemistry , Meningococcal Vaccines/chemistry , Mice , Polysaccharides, Bacterial/chemistry
5.
Vaccine ; 31(42): 4827-33, 2013 Oct 01.
Article in English | MEDLINE | ID: mdl-23965218

ABSTRACT

Glycoconjugate vaccines are among the most effective and safest vaccines ever developed. Diphtheria toxoid (DT), tetanus toxoid (TT) and CRM197 have been mostly used as protein carriers in licensed vaccines. We evaluated the immunogenicity of serogroup A, C, W-135 and Y meningococcal oligosaccharides conjugated to CRM197, DT and TT in naïve mice. The three carriers were equally efficient in inducing an immune response against the carbohydrate moiety in immunologically naïve mice. The effect of previous exposure to different dosages of the carrier protein on the anti-carbohydrate response was studied using serogroup A meningococcal (MenA) saccharide conjugates as a model. CRM197 showed a strong propensity to positively prime the anti-carbohydrate response elicited by its conjugates or those with the antigenically related carrier DT. Conversely in any of the tested conditions TT priming did not result in enhancement of the anti-carbohydrate response elicited by the corresponding conjugates. Repeated exposure of mice to TT or to CRM197 before immunization with the respective MenA conjugates resulted in a drastic suppression of the anti-carbohydrate response in the case of TT conjugate and only in a slight reduction in the case of CRM197. The effect of carrier priming on the anti-MenA response of DT-based conjugates varied depending on their carbohydrate to protein ratio. These data may have implications for human vaccination since conjugate vaccines are widely used in individuals previously immunized with DT and TT carrier proteins.


Subject(s)
Bacterial Proteins/administration & dosage , Diphtheria Toxoid/administration & dosage , Drug Carriers/administration & dosage , Meningococcal Vaccines/immunology , Tetanus Toxoid/administration & dosage , Animals , Meningococcal Vaccines/administration & dosage , Mice , Neisseria meningitidis, Serogroup A/immunology , Neisseria meningitidis, Serogroup C/immunology , Neisseria meningitidis, Serogroup W-135/immunology , Neisseria meningitidis, Serogroup Y/immunology , Polysaccharides, Bacterial/immunology , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...